DVAX vs. BVS

Last updated Jun 4, 2026

DVAX (Dynavax Technologies Corporation) and BVS (Bioventus Inc.) are both stocks. Both are in the Healthcare sector — DVAX in Drug Manufacturers - Specialty & Generic, BVS in Medical Devices. At a 0.21 correlation, their price movements are largely independent.

Performance

DVAX vs. BVS - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Dynavax Technologies Corporation (DVAX) and Bioventus Inc. (BVS). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

DVAX

• 1D: —
• 1M: —
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

BVS

• 1D: 5.43%
• 1M: -15.93%
• YTD: 14.92%
• 6M: 12.95%
• 1Y: 28.38%
• 3Y*: 42.42%
• 5Y*: -13.88%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

DVAX vs. BVS - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
DVAX Dynavax Technologies Corporation	0.78%	20.44%	-8.66%	31.39%	-24.38%	47.64%
BVS Bioventus Inc.	14.92%	-29.14%	99.24%	101.92%	-81.99%	-24.57%

Correlation

The correlation between DVAX and BVS is 0.20, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.20
Correlation (3Y) Calculated over the trailing 3-year period	0.21
Correlation (5Y) Calculated over the trailing 5-year period	0.22
Correlation (All Time) Calculated using the full available price history since Feb 12, 2021	0.21

Fundamentals

Market Cap DVAX : $2.12B BVS : $598.57M
EPS DVAX : -$0.32 BVS : $0.41
PS Ratio DVAX : 6.44 BVS : 1.02
PB Ratio DVAX : 3.96 BVS : 3.17
Total Revenue (TTM) DVAX : $330.51M BVS : $576.30M
Gross Profit (TTM) DVAX : $274.90M BVS : $390.14M
EBITDA (TTM) DVAX : -$25.65M BVS : $98.72M

Return for Risk

DVAX vs. BVS — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

BVS

BVS Risk / Return Rank: 61
BVS Sharpe Ratio Rank: 60
BVS Sortino Ratio Rank: 59
BVS Omega Ratio Rank: 56
BVS Calmar Ratio Rank: 62
BVS Martin Ratio Rank: 70

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

DVAX vs. BVS - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Dynavax Technologies Corporation (DVAX) and Bioventus Inc. (BVS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

Sharpe Ratios by Period

	DVAX	BVS	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	—	0.56	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	-0.17	—
Sharpe Ratio (All Time) Calculated using the full available price history	—	-0.18	—

Drawdowns

Drawdown Indicators

	DVAX	BVS	Difference
Max Drawdown Largest peak-to-trough decline	—	-95.18%	—
Max Drawdown (1Y) Largest decline over 1 year	—	-27.51%	—
Max Drawdown (3Y) Largest decline over 3 years	—	-55.22%	—
Max Drawdown (5Y) Largest decline over 5 years	—	-95.07%	—
Current Drawdown Current decline from peak	—	-55.49%	—
Average Drawdown Average peak-to-trough decline	—	-56.39%	—
Ulcer Index Depth and duration of drawdowns from previous peaks	—	7.50%	—

Volatility

Volatility by Period

	DVAX	BVS	Difference
Volatility (1M) Calculated over the trailing 1-month period	—	19.59%	—
Volatility (6M) Calculated over the trailing 6-month period	—	32.94%	—
Volatility (1Y) Calculated over the trailing 1-year period	—	50.58%	—
Volatility (5Y) Calculated over the trailing 5-year period, annualized	—	81.05%	—
Volatility (10Y) Calculated over the trailing 10-year period, annualized	—	80.08%	—

Dividends

DVAX vs. BVS - Dividend Comparison

Neither DVAX nor BVS has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

DVAX vs. BVS - Profitability Comparison

The chart below illustrates the profitability comparison between Dynavax Technologies Corporation and Bioventus Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

DVAX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Dynavax Technologies Corporation reported a gross profit of 80.47M and revenue of 94.88M. Therefore, the gross margin over that period was 84.8%.

BVS - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Bioventus Inc. reported a gross profit of 90.77M and revenue of 132.09M. Therefore, the gross margin over that period was 68.7%.

DVAX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Dynavax Technologies Corporation reported an operating income of 21.27M and revenue of 94.88M, resulting in an operating margin of 22.4%.

BVS - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Bioventus Inc. reported an operating income of 8.42M and revenue of 132.09M, resulting in an operating margin of 6.4%.

DVAX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Dynavax Technologies Corporation reported a net income of 26.93M and revenue of 94.88M, resulting in a net margin of 28.4%.

BVS - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Bioventus Inc. reported a net income of 3.11M and revenue of 132.09M, resulting in a net margin of 2.4%.

Frequently Asked Questions

Can I hold both DVAX and BVS in my portfolio?

DVAX and BVS have a correlation of 0.20, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.